Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

The reason staggering numbers are achievable (with no

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Mellowmood77 Member Profile
Member Level 
Followed By 25
Posts 525
Boards Moderated 0
Alias Born 04/30/19
160x600 placeholder
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascep... GlobeNewswire Inc. - 8/8/2019 4:30:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares GlobeNewswire Inc. - 7/29/2019 5:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2019 4:32:58 PM
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019 GlobeNewswire Inc. - 7/24/2019 6:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2019 5:01:04 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/18/2019 11:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 4:38:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 4:02:07 PM
Amarin Announces $400,000,000 Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/17/2019 4:01:00 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:15:19 AM
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance GlobeNewswire Inc. - 7/2/2019 6:00:00 AM
Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences GlobeNewswire Inc. - 6/21/2019 1:39:19 PM
Mellowmood77 Member Level  Tuesday, 09/17/19 06:32:41 PM
Re: Yoyippie post# 214845
Post # of 219195 
The reason staggering numbers are achievable (with no limit on supply) is because there is no competition, currently.

Statins were all competing with each other and in 2009 had near $40 billion combined in world wide revenue. They also got to a slow start and skepticism from the medical community when a drug similar to the first statin was found to be toxic to animals.

Vascepa doesn’t have to worry about a slow start as much because it is in effect piggy backing on current statin users. And it has the ability to do this because of it’s unprecedented 16k/QALY cost effectiveness. It’s a cheap drug and can be mass marketed to the 200 million world wide statin users. The drug will most likely not be approved for ALL statin users but as we gain momentum I believe we will be.

Imagine Lipitor coming in and having the entire statin market to itself today at brand name costs. That’s what Vascepa has or should have when approved by the FDA.

That’s why the most important thing Amarin can do is increase supply, educate consumers (DTC), and educate doctors. But really, supply will be THE limiting factor turning us into a mega blockbuster and I hope a large portion of the money raised is aimed towards this bottleneck.

So yea if 10-15 million Americans get on Vascepa, 10-15 million Europeans get on Vascepa, and another 10-15 million from the rest of the world get on Vascepa, we can surpass STAGGERING numbers in worldwide revenue. And that’s keeping it at the insanely low cost we are currently at.

It’s also why we haven’t been bought out yet. Because JT knows this (he’s mentioned 70 million people how many times now?) and will not sell the company cheap.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist